Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

NCT02150824 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: BI 187004
DRUG: Placebo
DRUG: BI 187004
DRUG: BI 187004
DRUG: BI 187004

Sponsor

Boehringer Ingelheim